Preemptive antiviral therapy guided by the viral load present in patient blood (measured by quantitative real-time PCR assays) is currently the mainstay strategy for the prevention of CMV end-organ disease in the allogeneic stem cell transplantation (allo-SCT) setting. 1 Although the effectiveness of this preventative therapeutic approach is beyond doubt, the occurrence of recurrent episodes of CMV DNAemia remains a problem as the incidence rates can still exceed 50% of patients in certain allo-SCT modalities. 2 Available guideline recommendations and expert opinions on CMV infection management in allo-SCT recipients are rather imprecise about when preemptive antiviral treatment should be interrupted. [3] [4] [5] [6] [7] A recent national survey revealed wide variation in the criterion for preemptive antiviral therapy cessation across Spanish allo-SCT transplant programs, 8 a scenario which is also likely to occur in transplant centers in other countries. It is common practice to withdraw antiviral therapy after documentation of either one or two consecutive negative PCR results (undetectable CMV DNA load) after a minimum of 2 weeks of therapy, although no data currently support the preferential use of one strategy over the other. In this study, we investigated the potential effect of the length of antiviral treatment courses for primary (initial) episodes of CMV DNAemia on the incidence of recurrences.
This prospective non-randomized study included 38 consecutive allo-SCT recipients (group A) with detectable CMV DNAemia (any level of CMV DNA present in plasma) after transplant. These patients underwent allo-SCT at the University Clinic Hospital of Valencia between May 2014 and December 2016; no exclusion criteria were established. Preemptive antiviral therapy was initiated either upon detection of a CMV DNA load 41000 copies/mL (1500 IU/mL), 9 as quantified by means of the new RealTime CMV PCR assay from Abbott Molecular (Des Plaines, IL, USA), or via documentation of a CMV DNA doubling time (dt) ⩽ 2 days, whichever came first. 10 The CMV dt was calculated using the CMV DNA values quantified in the first two positive QRT-PCR results, as described elsewhere. 10, 11 We previously showed that both strategies resulted in a comparable recurrent CMV DNAemia incidence rate. 10 Antiviral therapy was suspended at the first negative (undetectable) PCR result (o 20 copies/mL (31 IU/mL)), 8 irrespective of the number of days the patient had received antiviral therapy.
A historical cohort (group B), consisting of 40 consecutive allo-SCT recipients with post-transplant CMV DNAemia, was used for comparison purposes; these patients underwent allo-SCT between May 2012 and April 2014 and antiviral therapy was initiated upon detection of 41000 CMV DNA copies/mL. 9 CMV DNA load in these historical cases was quantified using the same real-time PCR (new RealTime CMV from Abbott). Antiviral therapy was discontinued after two consecutive negative PCR results after a minimum of 2 weeks treatment. The preemptive antiviral treatment scheme and plasma CMV DNA load-monitoring schedule were similar in both groups. Namely, patients were treated with oral valganciclovir (900 mg/12 h) or i.v. ganciclovir (5 mg/kg/12 h), using i.v. foscarnet (60 mg/kg/8 h) as a second-line therapy. Plasma CMV DNA load monitoring was conducted once or twice a week during episodes of CMV DNAemia, once a week up to day 120 after transplant, and at each planned visit at the outpatient clinic afterwards.
Two primary end points were defined: (i) the overall cumulative incidence of recurrent episodes of CMV DNAemia, defined as those that occurred at least 15 days after clearance (first negative PCR result) of the initial episode, and (ii) the cumulative incidence of recurrent episodes that required antiviral therapy; the study period comprised the first year after allo-SCT. Data on 16 patients in the prospective cohort were previously published. 10 The study was approved by the local Review Board and the Ethics Committee and all patients gave their written informed consent prior to participating in the study.
As shown in Table 1 , patients included in both study groups were matched in terms of demographics, baseline (pre-transplant) characteristics, incidence of severe (grades II-IV) aGvHD and virological features of the initial episodes of CMV DNAemia (that is, the time frame for their occurrence, magnitude of the initial and peak CMV DNA load values, CMV DNA dt and the episode duration). In the prospective cohort, the inception of antiviral therapy was prompted by a CMV DNA dt ⩽ 2 days in five patients and by a CMV DNA load 41000 copies/mL in the remaining 16 patients. The number of primary CMV DNAemia episodes requiring administration of preemptive antiviral therapy was also comparable between groups (P = 0.39).
The cumulative incidence of recurrent CMV DNAemia (Figure 1a) , the number of documented recurrences and the virological features of the first-relapse CMV DNAemia episode did not significantly differ between groups (Table 1 ). Interestingly, the cumulative incidence of overall (Figure 1b) or preemptively treated recurrent CMV DNAemia (first-relapse episode; Figure 1c ) in patients who received antiviral therapy for the initial CMV DNAemia episode were even lower in the prospective cohort than in the historical cohort, although the differences did not reach statistical significance.
Cox proportional hazard regression analyses indicated that the strategy of discontinuing preemptive antiviral therapy for initial episodes of CMV DNAemia was not a significant risk factor for the recurrence of CMV DNAemia (group A versus group B: hazard ratio (HR), 0.68 (95% confidence interval (CI), 0.31-1.47; P = 0.33) for total recurrences, and HR, 0.33 (95% CI, 0.08-1.26; P = 0.11) for treated recurrences). In these models, none of the covariates tested, including the type of allo-SCT (related versus unrelated/ HLA-matched versus HLA-mismatched), the stem cell source, donor and recipient-pair CMV serostatus, conditioning regimen (myeloablative versus non-myeloablative), occurrence of aGvHD, and aGvHD prophylaxis regimen were significantly associated with the risk of recurrent CMV DNAemia (data not shown).
Griffiths et al. 12 recently conducted an open-label controlled trial in solid organ transplant and allo-SCT recipients. Patients were Frequency comparisons were performed using the χ 2 -test (Fisher exact test). The non-parametric Mann-Whitney U-test was used for unpaired continuous data. Two-tailed P-values o0.05 were deemed to be significant. These statistical analyses were performed using SPSS software (version 20.0, Chicago, IL, USA). c Acute GvHD was diagnosed and graded as previously reported. 13 d Only episodes in which dt could be calculated.
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The duration of a given episode of CMV DNAemia was defined as the interval between the day of the first positive PCR result and the day of the first negative (undetectable) result. Letter to the Editor randomized into two groups: in one, the antiviral treatment was interrupted after two consecutive negative PCR results (CMV DNA load o 168 IU/mL), in the other, the threshold used to prompt the inception of antiviral therapy (CMV DNA load o 2520 IU/mL) was used. More relapsing episodes requiring the administration of antiviral therapy were observed in the latter group, although the difference was not statistically significant. In the current study, we compared the clinical safety, as inferred by the cumulative incidence of relapsing episodes of CMV DNAemia (total number or only those requiring antiviral treatment), of two preemptive antiviral therapy strategies for allo-SCT recipients, which differed in the criterion we used for treatment interruption. Our study adds to the work of Griffiths et al. 12 by showing that the cessation of antiviral treatment at detection of the first negative CMV DNA load is at least as safe as doing so upon documentation of two consecutive PCR results. As expected, this novel approach led to shorter antiviral treatment courses (although these could not be reduced to o14 days), and an associated decrease in direct costs. It may have also led to a decrease in indirect costs because administering shorter antiviral treatment courses also likely translates into lower drug-related toxicity effects. However, this aspect was not specifically addressed in this current study and should be considered in future studies.
It is worth noting that our study has several limitations that must be acknowledged. First, the two strategies we evaluated differed in the criteria used for initiating antiviral therapy as in the prospective cohort either the detection of a CMV DNA load 41000 copies/mL or documentation of a CMV DNA dt ⩽ 2 days. Nevertheless, the decision to administer antiviral treatment was made based on CMV DNA dt values only in a minority of patients (5 from 21), and so is unlikely to have affected our conclusions. Second, the relatively small size of our prospective cohort and the non-randomized nature of the study undermine its robustness. Hence, only controlled and adequately powered studies can definitively prove the effectiveness and clinical safety of the strategy we outline here. cohorts. Cumulative incidence of overall recurrent (b) or treated (c) CMV DNAemia following an initial episode that required the inception of antiviral therapy in patients managed using strategy A or B. The cumulative incidence values (and 95% CIs) are shown. These were estimated using the cumulative incidence method (marginal probability) with the statistical software R (http://www.r-project.org/). The Gray test was used for comparisons. Death or relapse of the underlying disease was considered as competitive events. P-values of ⩽ 0.05 were deemed to be statistically significant.
